Journal of medicinal chemistryHistone Deacetylase InhibitorsHumansColorectal NeoplasmsAnimalsAntineoplastic Agents
Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo.
Gabriele Carullo, Federica Falbo, Valeria Tudino, Jiazhao Song, Marianna Fava, Anna Fontana, Adrian Koch, Anita Heiß, Katharina Erlenbach-Wuensch, Giovanna Panzeca, Simone Brogi, Alessia Bichicchi, Simona Saponara, Fabio Fusi, Fabrizio Vincenzi
Published: 202610.1021/acs.jmedchem.5c02237
Abstract
Class I histone deacetylases (HDACs) are frequently overexpressed in colorectal cancer (CRC). Combining computational, synthetic, and biological efforts, we developed novel o-aminobenzamide-based HDAC inhibitors (HDACis) optimized for class I enzyme-…
Preview only. Read the full abstract at the source